AI-Assisted Detection and Staging of Gastric Cancer Using Contrast-Enhanced CT
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-85
SponsorThe First Affiliated Hospital with Nanjing Medical University
About this trial
Accurate preoperative assessment of gastric cancer stage guides eligibility for endoscopic resection, extent of gastrectomy and lymphadenectomy, selection for neoadjuvant therapy, and use of staging laparoscopy. Contrast-enhanced CT (CECT) is guideline-endorsed for initial staging, yet performance varies across institutions and readers. This study will evaluate an artificial-intelligence (AI) system that analyzes routine CECT to detect gastric cancer and assign four-class T stage (T1-T4) and N stage (N0-N3) .
Eligibility criteria
Qualifiers
pathologically confirmed gastric cancer;
preoperative contrast-enhanced CT performed;
no evidence of distant metastasis on baseline staging;
curative-intent management with complete postoperative histopathology.
Disqualifiers
prior treatment before surgery;
non-diagnostic or poor-quality CT precluding evaluation.
Trial design
Treatments tested in this trial
- CT scan
Treatment groups
8,000 Participants
are divided into 3 treatment groupsLocations
1The First Affiliated Hospital of Nanjing Medical University NanjingJiangsu, China
Sponsors and collaborators
The First Affiliated Hospital with Nanjing Medical University
Lead sponsor
Jiangsu Cancer Institute & Hospital
Collaborator
Zhengzhou University
Collaborator
Peking University First Hospital
Collaborator
Source ClinicalTrials.gov